Viome Life Sciences, a biotechnology company, received $86.5 million in an oversubscribed Series C funding round, which it will use to grow its business, the company announced Friday.
The Bellevue, Washington-based startup sells at-home testing and health products to consumers through its website. It offers a full body health test, a gut health test and an oral health test. The tests then leverage AI to provide consumers with insights on what’s leading to microbial imbalances and inflammation, and then Viome offers personalized food lists, probiotics and prebiotics to support consumers’ health. It also has an oral and throat cancer diagnostic test, which can detect cancer as early as stage one. What sets Viome apart from other testing companies like Grail and Exact Sciences is that it focuses on RNA instead of DNA.